Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Employees

v3.22.1
Employees
12 Months Ended
Dec. 31, 2021
Employees  
Employees

 

8. Employees

 

   

Year ended

December 31,

   

Year ended

December 31,

   

Year ended

December 31,

 
   

2021

Number

   

2020

Number

   

2019

Number

 
Number of employees                        
Average monthly number or persons (including directors) employed by the Group:                        
Research and development     61       66       83  
Management, administration and operations     8       13       11  
Number of employees     69       79       94  

 

Management includes employees who are involved in both research and development and administrative operations.

 

   

Year ended

December 31,

   

Year ended

December 31,

   

Year ended

December 31,

 
    2021     2020     2019  
    £     £     £  
Staff costs – included in research and development                        
Wages and salaries     2,989,066       3,443,726       3,663,845  
Social security costs     313,138       386,063       411,114  
Pension costs – defined contribution     94,938       130,339       145,223  
Share based payments     -       316,259       373,414  
Total staff costs     3,397,142       4,276,387       4,593,596  
Staff costs – included in administrative expenses                        
Wages and salaries     877,752       703,366       766,107  
Social security costs     56,646       99,040       82,236  
Pension costs – defined contribution     42,034       24,548       38,372  
Share based payments     -       256,803       462,378  
Total staff costs     976,432       1,083,757       1,349,093  
Staff costs – combined                        
Wages and salaries     3,866,818       4,147,091       4,429,952  
Social security costs     369,784       485,102       493,350  
Pension costs – defined contribution     136,972       154,887       183,595  
Share based payments     -       573,062       835,792  
Total staff costs     4,373,574       5,360,142       5,942,689  

 

 

TC BIOPHARM (HOLDINGS) PLC

 

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)

 

8. Employees (continued)

 

Directors’ remuneration

 

Year ended

December 31,

    Year ended December 31,    

Year ended

December 31,

 
    2021     2020     2019  
    £     £     £  
Directors’ remuneration in respect of qualifying services     1,046,324       967,651       676,557  
Directors’ employer’s pension contributions     15,001       14,376       12,453  
Directors remuneration     1,061,325       982,027       689,010  

 

The total remuneration of the highest paid or receivable by the highest paid director in the year ended December 31, 2021 was £332,468 (2020: £365,194 and 2019: £294,259). The Group pension contributions in respect of the highest paid director totaled £Nil for the year to December 31, 2021 (2020: £Nil and 2019: £8,111). The highest paid director did not exercise any share options in the period. No other directors exercised share options in the period.